ACS Medicinal Chemistry Letters
Letter
(4) McKerrecher, D.; Allen, J. V.; Caulkett, P. W. R.; Donald, C. S.;
Fenwick, M. L.; Grange, E.; Johnson, K. M.; Johnstone, C.; Jones, C.
D.; Pike, K. G.; Rayner, J. W.; Walker, R. P. Design of a potent, soluble
glucokinase activator with excellent in vivo efficacy. Bioorg. Med. Chem.
Lett. 2006, 16, 2705−2709.
(5) (a) Waring, M. J.; Johnstone, C.; McKerrecher, D.; Pike, K. G.;
Robb, G. Matrix-based multiparameter optimization of glucokinase
activators: the discovery of AZD1092. Med. Chem. Commun. 2011, 2,
775−779. (b) Waring, M. J.; Clarke, D. S.; Fenwick, M. D.; Godfrey,
L.; Groombridge, S. D.; Johnstone, C.; McKerrecher, D.; Pike, K. G.;
Rayner, J. W.; Robb, G. R.; Wilson, I. Property based optimization of
glucokinase activators: discovery of phase IIb clinical candidate
AZD1656. Med. Chem. Commun. 2012, 3, 1077−1081.
(15) Chen, S.; Corbett, W. L.; Guertin, K. R.; Haynes, N.; Kester, R.
F.; Mennona, F. A.; Mischke, S. G.; Qian, Y.; Sarabu, R.; Scott, N. R.;
Thakkar, K. C. 5-Substituted-Six-Membered Heteroaromatic Glucokinase
Activators. U.S. Patent 7,132,425, 2006.
(16) Kolb, H. C.; VanNieuwenhze, M. S.; Sharpless, K. B. Catalytic
asymmetric dihydroxylation. Chem. Rev. 1994, 94, 2483−2547.
(17) Berthel, S. J.; Brinkman, J. A.; Hayden, S.; Haynes, N. E.; Kester,
R. F.; McDermott, L. A.; Qian, Y.; Sarabu, R.; Scott, N. R.; Tilley, J. W.
Pyrrolidinone Glucokinase Activators. U.S. Patent 7,741,327, 2010.
(18) Berthel, S. J.; Haynes, N. E.; Kester, R. F.; McDermott, L. A.;
Qian, Y.; Sarabu, R.; Scott, N. R.; Tilley, J. W. Pyridazinone Glucokinase
Activators. U.S. Patent 8,258,134, 2012.
(6) Mao, W.; Ning, M.; Liu, Z.; Zhu, Q.; Leng, Y.; Zhang, A. Design,
synthesis, and pharmacological evaluation of benzamide derivatives as
glucokinase activators. Bioorg. Med. Chem. 2012, 20, 2982−2991.
(7) Meininger, G. E.; Scott, R.; Alba, M.; Shentu, Y.; Luo, E.; Amin,
H.; Davies, M. J.; Kaufman, K. D.; Goldstein, B. J. Effects of MK-0941,
a novel glucokinase activator, on glycemic control in insulin-treated
patients with type 2 diabetes. Diabetes Care 2011, 34, 2560−2566.
(8) Takahashi, K.; Hashimoto, N.; Nakama, C.; Kamata, K.; Sasaki,
K.; Yoshimoto, R.; Ohyama, S.; Hosaka, H.; Maruki, H.; Nagata, Y.;
Eiki, J. I.; Nishimura, T. The design and optimization of a series of 2-
(pyridin-2-yl)-1H-benzimidazole compounds as allosteric glucokinase
activators. Bioorg. Med. Chem. 2009, 17, 7042−7051.
(9) Nishimura, T.; Iino, T.; Mitsuya, M.; Bamba, M.; Watanabe, H.;
Tsukahara, D.; Kamata, K.; Sasaki, K.; Ohyama, S.; Hosaka, H.;
Futamura, M.; Nagata, Y.; Eiki, J. I. Identification of novel and potent
2-amino benzamide derivatives as allosteric glucokinase activators.
Bioorg. Med. Chem. Lett. 2009, 19, 1357−1360.
(10) Bertram, L. S.; Black, D.; Briner, P. H.; Chatfield, R.; Cooke, A.;
Fyfe, M. C. T.; Murray, P. J.; Naud, F.; Nawano, M.; Procter, M. J.;
Rakipovski, G.; Rasamison, C. M.; Reynet, C.; Schofield, K. L.; Shah,
V. K.; Spindler, F.; Taylor, A.; Turton, R.; Williams, G. M.; Wong-Kai-
In, P.; Yasuda, K. SAR, pharmacokinetics, safety, and efficacy of
glucokinase activating 2-(4-sulfonylphenyl)-N-thiazol-2-ylacetamides:
discovery of PSN-GK1. J. Med. Chem. 2008, 51, 4340−4345.
(11) Bebernitz, G. R.; Beaulieu, V.; Dale, B. A.; Deacon, R.; Duttaroy,
A.; Gao, J.; Grondine, M. S.; Gupta, R. C.; Kakmak, M.; Kavana, M.;
Kirman, L. C.; Liang, J.; Maniara, W. M.; Munshi, S.; Nadkarni, S. S.;
Schuster, H. F.; Stams, T.; St. Denny, I.; Taslimi, P. M.; Vash, B.;
Caplan, S. L. Investigation of functionally liver selective glucokinase
activators for the treatment of type 2 diabetes. J. Med. Chem. 2009, 52,
6142−6152.
(12) Pfefferkorn, J. A.; Guzman-Perez, A.; Litchfield, J.; Aiello, R.;
Treadway, J. L.; Pettersen, J.; Minich, M. L.; Filipski, K. J.; Jones, C. S.;
Tu, M.; Aspnes, G.; Risley, H.; Bian, J.; Stevens, B. D.; Bourassa, P.;
D’Aquila, T.; Baker, L.; Barucci, N.; Robertson, A. S.; Bourbonais, F.;
Derksen, D. R.; MacDougall, M.; Cabrera, O.; Chen, J.; Lapworth, A.
L.; Landro, J. A.; Zavadoski, W. J.; Atkinson, K.; Haddish-Berhane, N.;
Tan, B.; Yao, L.; Kosa, R. E.; Varma, M. V.; Feng, B.; Duignan, D. B.;
El-Kattan, A.; Murdande, S.; Liu, S.; Ammirati, M.; Knafels, J.; DaSilva-
Jardine, P.; Sweet, L.; Liras, S.; Rolph, T. P. Discovery of (S)-6-(3-
cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)-
nicotinic acid as a hepatoselective glucokinase activator clinical
candidate for treating type 2 diabetes mellitus. J. Med. Chem. 2012,
55, 1318−1333.
(13) Sarabu, R.; Bizzarro, F. T.; Corbett, W. L.; Dvorozniak, M. T.;
Geng, W.; Grippo, J. F.; Haynes, N. E.; Hutchings, S.; Garofalo, L.;
Guertin, K. R.; Hilliard, D. W.; Kabat, M.; Kester, R. F.; Wang, K.;
Liang, Z.; Mahaney, P. E.; Marcus, L.; Matschinsky, F. M.; Moore, D.;
Racha, J.; Radinov, R.; Ren, Y.; Qi, L.; Pignatello, M.; Spence, C. L.;
Steele, T.; Tengi, J.; Grimsby, J. Discovery of Piragliatin-first
glucokinase activator studied in type 2 diabetic patients. J. Med.
Chem. 2012, 55, 7021−7036.
(14) Meanwell, N. A. Improving drug candidates by design: a focus
on physicochemical properties as a means of improving compound
disposition and safety. Chem. Res. Toxicol. 2011, 24, 1420−1456.
E
dx.doi.org/10.1021/ml400027y | ACS Med. Chem. Lett. XXXX, XXX, XXX−XXX